PMEF
ABOS icon

Point72 Middle East FZE’s Acumen Pharmaceuticals ABOS Stock Holding History

Point72 Middle East FZE’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,415
Closed -$13.9K – 1487
2023
Q1 		$13.9K Buy
+3,415
New +$17.8K ﹤0.01% 1464

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Middle East FZE's ABOS Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Acumen Pharmaceuticals (ABOS) in Q2 2023, closing a stake of 3,415 shares — an estimated $13.9K sold.

Point72 Middle East FZE first reported a position in ABOS in Q1 2023 and held it in 1 quarter. The position peaked at $13.9K in Q1 2023. 53 funds tracked by Wall St. Rank hold ABOS as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Acumen Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,415 Acumen Pharmaceuticals shares in Q2 2023, an estimated $13.9K.
  • Point72 Middle East FZE first reported a position in Acumen Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Acumen Pharmaceuticals position peaked at $13.9K in Q1 2023.
  • 53 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.